138 related articles for article (PubMed ID: 31007176)
1. Animal models for hepatocellular carcinoma.
Zhang HE; Henderson JM; Gorrell MD
Biochim Biophys Acta Mol Basis Dis; 2019 May; 1865(5):993-1002. PubMed ID: 31007176
[TBL] [Abstract][Full Text] [Related]
2. Experimental mouse models for hepatocellular carcinoma research.
Heindryckx F; Colle I; Van Vlierberghe H
Int J Exp Pathol; 2009 Aug; 90(4):367-86. PubMed ID: 19659896
[TBL] [Abstract][Full Text] [Related]
3. Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background.
Chung SI; Moon H; Kim DY; Cho KJ; Ju HL; Kim DY; Ahn SH; Han KH; Ro SW
BMC Gastroenterol; 2016 Jan; 16():13. PubMed ID: 26821924
[TBL] [Abstract][Full Text] [Related]
4. Inside-Out or Outside-In: Choosing the Right Model of Hepatocellular Cancer.
Monga SP
Gene Expr; 2020 Nov; 20(2):139-145. PubMed ID: 32503685
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-activated cytotoxic agent tirapazamine enhances hepatic artery ligation-induced killing of liver tumor in HBx transgenic mice.
Lin WH; Yeh SH; Yeh KH; Chen KW; Cheng YW; Su TH; Jao P; Ni LC; Chen PJ; Chen DS
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):11937-11942. PubMed ID: 27702890
[TBL] [Abstract][Full Text] [Related]
6. Zebrafish as a disease model for studying human hepatocellular carcinoma.
Lu JW; Ho YJ; Yang YJ; Liao HA; Ciou SC; Lin LI; Ou DL
World J Gastroenterol; 2015 Nov; 21(42):12042-58. PubMed ID: 26576090
[TBL] [Abstract][Full Text] [Related]
7. Mouse models of liver cancer: Progress and recommendations.
He L; Tian DA; Li PY; He XX
Oncotarget; 2015 Sep; 6(27):23306-22. PubMed ID: 26259234
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
9. Recombinant soluble gp130 protein reduces DEN-induced primary hepatocellular carcinoma in mice.
Hong J; Wang H; Shen G; Lin D; Lin Y; Ye N; Guo Y; Li Q; Ye N; Deng C; Meng C
Sci Rep; 2016 Apr; 6():24397. PubMed ID: 27080032
[TBL] [Abstract][Full Text] [Related]
10. Mouse models of liver cancer.
Caviglia JM; Schwabe RF
Methods Mol Biol; 2015; 1267():165-83. PubMed ID: 25636469
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma: risk factors other than HBV.
Villa E; Melegari M; Scaglioni PP; Trande P; Cesaro P; Manenti F
Ital J Gastroenterol; 1991; 23(7):457-60. PubMed ID: 1660333
[TBL] [Abstract][Full Text] [Related]
13. Novel mouse models of hepatocarcinogenesis with stepwise accumulation of genetic alterations.
Kim SK; Marusawa H; Eso Y; Chiba T; Kudo M
Dig Dis; 2013; 31(5-6):454-8. PubMed ID: 24281020
[TBL] [Abstract][Full Text] [Related]
14. Diet-Induced Obesity Enhances Progression of Hepatocellular Carcinoma through Tenascin-C/Toll-Like Receptor 4 Signaling.
Benbow JH; Thompson KJ; Cope HL; Brandon-Warner E; Culberson CR; Bossi KL; Li T; Russo MW; Gersin KS; McKillop IH; deLemos AS; Schrum LW
Am J Pathol; 2016 Jan; 186(1):145-58. PubMed ID: 26603137
[TBL] [Abstract][Full Text] [Related]
15. Preclinical mouse models of hepatocellular carcinoma: An overview and update.
Gu CY; Lee TKW
Exp Cell Res; 2022 Mar; 412(2):113042. PubMed ID: 35101391
[TBL] [Abstract][Full Text] [Related]
16. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target.
Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA
Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986
[TBL] [Abstract][Full Text] [Related]
17. Animal models as a tool in hepatocellular carcinoma research: A Review.
Santos NP; Colaço AA; Oliveira PA
Tumour Biol; 2017 Mar; 39(3):1010428317695923. PubMed ID: 28347231
[TBL] [Abstract][Full Text] [Related]
18. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
19. Two-stage model of chemically induced hepatocellular carcinoma in mouse.
Luo M; Yang F; Huang SX; Kuang ZP; Luo XL; Li YD; Wu JN; Xie YA
Oncol Res; 2013; 20(11):517-28. PubMed ID: 24063282
[TBL] [Abstract][Full Text] [Related]
20. Aldo-Keto Reductases as Early Biomarkers of Hepatocellular Carcinoma: A Comparison Between Animal Models and Human HCC.
Torres-Mena JE; Salazar-Villegas KN; Sánchez-Rodríguez R; López-Gabiño B; Del Pozo-Yauner L; Arellanes-Robledo J; Villa-Treviño S; Gutiérrez-Nava MA; Pérez-Carreón JI
Dig Dis Sci; 2018 Apr; 63(4):934-944. PubMed ID: 29383608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
